David Cunningham

发表

David Cunningham, D. Cunningham, 2006 .

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Sabine Tejpar, Mauro Delorenzi, Dirk Klingbiel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study

Nina Tunariu, Andrea Lampis, Mihaela Rata, 2017, Gut.

Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.

David Cunningham, D. Cunningham, I. Chau, 2009, Recent patents on anti-cancer drug discovery.

The Value of Source Data Verification in a Cancer Clinical Trial

Catrin Tudur Smith, John P. Neoptolemos, Janet Dunn, 2012, PloS one.

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Armando Santoro, David Khayat, David Cunningham, 2004, The New England journal of medicine.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.

Naotoshi Sugimoto, Yasuhiro Shimada, David Ferry, 2014, The Lancet. Oncology.

Analysis of tumour gene expression following chemotherapeutic treatment of patients with bowel cancer

Paul Workman, David Cunningham, P. Workman, 1999, Nature Genetics.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnostic accuracy of high-resolution MRI as a method to predict potentially safe endoscopic and surgical planes in patients with early rectal cancer

Diana Tait, David Cunningham, D. Tait, 2017, BMJ open gastroenterology.

Molecular and clinical determinants of survival following relapse after treatment of stage ii-iii colon cancer (cc). results of the translational study on the petacc 3-eortc 40993-sakk 60-00 trial

Sabine Tejpar, Dirk Klingbiel, M. Delorenzi, 2010 .

Multiplexed single cell protein expression analysis in solid tumours using a miniaturised microfluidic assay

David R. Klug, Keith R. Willison, David Cunningham, 2017 .

PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.

Fiona Campbell, Bal Sanghera, Andrew Scarsbrook, 2018, Health technology assessment.

The role of personalized medicine in metastatic colorectal cancer: an evolving landscape

David Cunningham, D. Cunningham, E. Smyth, 2013, Therapeutic advances in gastroenterology.

The use of 18F-FDG PET/CT in colorectal liver metastases—comparison with CT and liver MRI

Dow-Mu Koh, Gary Cook, Bhupinder Sharma, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.

Fredrik Mattsson, Jesper Lagergren, David Cunningham, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.

Anthony J. Swerdlow, David C. Linch, Alan Horwich, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-0003NAPOLI-1: RANDOMIZED PHASE 3 STUDY OF MM-398 (NAL-IRI), WITH OR WITHOUT 5-FLUOROURACIL AND LEUCOVORIN, VERSUS 5-FLUOROURACIL AND LEUCOVORIN, IN METASTATIC PANCREATIC CANCER PROGRESSED ON OR FOLLOWING GEMCITABINE-BASED THERAPY

David Cunningham, G. Bodoky, D. Cunningham, 2014 .

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

Andrea Sottoriva, Nina Tunariu, Paul Workman, 2018, Science.

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

Christian Jacques, Lucile Awad, David Cunningham, 1998, The Lancet.

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

Sue Chua, Alex Pearson, James Campbell, 2016, Cancer discovery.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Yan-Shen Shan, Paul Ross, Daniel Palmer, 2016, The Lancet.

Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.

David Cunningham, D. Cunningham, K. Danenberg, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.